Compare Stocks: PHVS, CYTK, SYRE, and PCVX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$79.20 +2.2%	$80.27	$35.22 ▼ $88.31	$9.64B	0.38	1.87 million shs	1.24 million shs
PCVX Vaxcyte	$61.09	$57.12	$29.87 ▼ $65.00	$9.09B	1.23	944,508 shs	891,649 shs
PHVS Pharvaris	$37.00 -0.6%	$34.47	$20.65 ▼ $38.13	$2.44B	-2.31	639,584 shs	437,987 shs
SYRE Spyre Therapeutics	$93.61 -12.8%	$98.29	$14.51 ▼ $110.18	$8.23B	3.03	823,744 shs	3.11 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	+2.25%	+1.88%	-1.76%	+3.11%	+107.38%
PCVX Vaxcyte	0.00%	-3.49%	+10.07%	+19.64%	+101.95%
PHVS Pharvaris	-0.62%	+2.01%	+8.92%	+23.91%	+54.17%
SYRE Spyre Therapeutics	-12.81%	-14.06%	-6.43%	+29.82%	+448.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$79.20 +2.2%	$80.27	$35.22 ▼ $88.31	$9.64B	0.38	1.87 million shs	1.24 million shs
PCVX Vaxcyte	$61.09	$57.12	$29.87 ▼ $65.00	$9.09B	1.23	944,508 shs	891,649 shs
PHVS Pharvaris	$37.00 -0.6%	$34.47	$20.65 ▼ $38.13	$2.44B	-2.31	639,584 shs	437,987 shs
SYRE Spyre Therapeutics	$93.61 -12.8%	$98.29	$14.51 ▼ $110.18	$8.23B	3.03	823,744 shs	3.11 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	+2.25%	+1.88%	-1.76%	+3.11%	+107.38%
PCVX Vaxcyte	0.00%	-3.49%	+10.07%	+19.64%	+101.95%
PHVS Pharvaris	-0.62%	+2.01%	+8.92%	+23.91%	+54.17%
SYRE Spyre Therapeutics	-12.81%	-14.06%	-6.43%	+29.82%	+448.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTK Cytokinetics	2.86	Moderate Buy	$102.20	29.04% Upside
PCVX Vaxcyte	2.50	Moderate Buy	$86.00	40.78% Upside
PHVS Pharvaris	2.86	Moderate Buy	$51.08	38.05% Upside
SYRE Spyre Therapeutics	2.87	Moderate Buy	$109.69	17.18% Upside

Current Analyst Ratings Breakdown

Latest PHVS, CYTK, SYRE, and PCVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	SYRE Spyre Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$135.00 ➝ $127.00
8/26/2026	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$130.00 ➝ $123.00
8/26/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$132.00 ➝ $121.00
8/14/2026	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	PHVS Pharvaris	New Street Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$60.00
8/14/2026	PHVS Pharvaris	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	PHVS Pharvaris	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/13/2026	CYTK Cytokinetics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$95.00 ➝ $110.00
8/13/2026	PHVS Pharvaris	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Overweight
8/13/2026	PHVS Pharvaris	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/13/2026	CYTK Cytokinetics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$97.00 ➝ $103.00

(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTK Cytokinetics	$88.04M	111.94	N/A	N/A	($1.39) per share	-56.98
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$18.53 per share	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	$5.35 per share	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	$10.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTK Cytokinetics	-$784.96M	-$7.22	N/A	N/A	N/A	-1,321.12%	N/A	-51.01%	11/4/2026 (Estimated)
PCVX Vaxcyte	-$766.63M	-$7.63	N/A	N/A	N/A	N/A	-37.56%	-33.62%	11/3/2026 (Estimated)
PHVS Pharvaris	-$198.79M	-$3.05	N/A	N/A	N/A	N/A	-61.40%	-56.00%	11/11/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)

Latest PHVS, CYTK, SYRE, and PCVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	PHVS Pharvaris	-$0.7467	-$0.81	-$0.0633	-$0.80	N/A	N/A
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	-$1.50	+$0.13	-$1.50	$17.59 million	$28.62 million
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.06	-$1.97	+$0.09	-$1.97	$12.50 million	N/A
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTK Cytokinetics	N/A	6.66	6.66
PCVX Vaxcyte	N/A	5.72	5.72
PHVS Pharvaris	N/A	11.94	11.94
SYRE Spyre Therapeutics	N/A	18.53	18.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTK Cytokinetics	N/A
PCVX Vaxcyte	96.78%
PHVS Pharvaris	N/A
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
CYTK Cytokinetics	2.60%
PCVX Vaxcyte	3.30%
PHVS Pharvaris	11.84%
SYRE Spyre Therapeutics	15.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTK Cytokinetics	250	124.43 million	121.20 million	Optionable
PCVX Vaxcyte	160	148.81 million	143.89 million	Optionable
PHVS Pharvaris	30	65.41 million	57.66 million	Not Optionable
SYRE Spyre Therapeutics	73	87.94 million	74.14 million	Optionable

PHVS, CYTK, SYRE, and PCVX Headlines

Recent News About These Companies

Spyre Therapeutics plunges; why analysts aren't sweating

August 26 at 7:31 PM | msn.com

SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis

August 26 at 1:10 PM | zacks.com

Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles

August 26 at 10:46 AM | benzinga.com

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down on Analyst Downgrade

August 26 at 10:19 AM | marketbeat.com

Biggest stock movers Wednesday: SYRE, INTU, SAP and more

August 26 at 9:30 AM | msn.com

Wedbush Adjusts Price Target on Spyre Therapeutics to $123 From $130, Maintains Outperform Rating

August 26 at 9:30 AM | finance.yahoo.com

Spyre Therapeutics (SYRE) Stock Plunges 14% on SPY072 Rheumatoid Arthritis Trial Results

August 26 at 9:30 AM | blockonomi.com

Spyre Therapeutics (NASDAQ:SYRE) Price Target Lowered to $123.00 at Wedbush

August 26 at 8:41 AM | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Given New $121.00 Price Target at BTIG Research

August 26 at 8:05 AM | marketbeat.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 26 at 3:18 AM | americanbankingnews.com

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

August 25 at 4:01 PM | globenewswire.com

Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?

August 24 at 12:31 PM | zacks.com

Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?

August 24 at 12:31 PM | zacks.com

SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It?

August 24 at 11:11 AM | zacks.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 21, 2026 | marketbeat.com

This stock’s already up nearly 600% over the past year

August 19, 2026 | msn.com

Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week High - Here's What Happened

August 18, 2026 | marketbeat.com

LifeSci Capital Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)

August 17, 2026 | theglobeandmail.com

Handelsbanken Fonder AB Makes New $2.31 Million Investment in Spyre Therapeutics, Inc. $SYRE

August 17, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Downgraded to Sell Rating by Wall Street Zen

August 16, 2026 | americanbankingnews.com

Wall Street Zen Downgrades Spyre Therapeutics (NASDAQ:SYRE) to Sell

August 16, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS, CYTK, SYRE, and PCVX Company Descriptions

Cytokinetics NASDAQ:CYTK

$79.20 +1.74 (+2.25%)

Closing price 08/26/2026 04:00 PM Eastern

Extended Trading

$79.47 +0.27 (+0.35%)

As of 07:40 AM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Vaxcyte NASDAQ:PCVX

$61.09 0.00 (0.00%)

Closing price 08/26/2026 04:00 PM Eastern

Extended Trading

$61.12 +0.03 (+0.05%)

As of 07:21 AM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Pharvaris NASDAQ:PHVS

$37.00 -0.23 (-0.62%)

Closing price 08/26/2026 04:00 PM Eastern

Extended Trading

$37.02 +0.02 (+0.05%)

As of 07:39 AM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Spyre Therapeutics NASDAQ:SYRE

$93.61 -13.75 (-12.81%)

Closing price 08/26/2026 04:00 PM Eastern

Extended Trading

$94.16 +0.55 (+0.59%)

As of 07:36 AM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHVS, CYTK, SYRE, and PCVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHVS, CYTK, SYRE, and PCVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHVS, CYTK, SYRE, and PCVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS, CYTK, SYRE, and PCVX Company Descriptions

Cytokinetics NASDAQ:CYTK

Vaxcyte NASDAQ:PCVX

Pharvaris NASDAQ:PHVS

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHVS, CYTK, SYRE, and PCVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHVS, CYTK, SYRE, and PCVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHVS, CYTK, SYRE, and PCVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS, CYTK, SYRE, and PCVX Company Descriptions

Cytokinetics NASDAQ:CYTK

Vaxcyte NASDAQ:PCVX

Pharvaris NASDAQ:PHVS

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools